Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why
Portfolio Pulse from Vandana Singh
Citi has initiated coverage on BridgeBio Pharma Inc (BBIO) with an optimistic outlook, citing the substantial market potential of acoramidis, especially after its recent Phase 3 successes in treating ATTR cardiomyopathy. Citi recommends a Buy/High Risk with a price target of $42. The analysts also anticipate that acoramidis could achieve blockbuster sales levels post its expected launch in H2 2024. Other promising candidates in BBIO's pipeline include infigratinib, encaleret, and BBP-418.
November 07, 2023 | 9:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citi's optimistic outlook and Buy/High Risk recommendation for BridgeBio Pharma, along with a price target of $42, could potentially boost investor confidence and positively impact the stock's short-term performance.
Citi's coverage initiation often influences investor sentiment. The optimistic outlook, based on the potential of acoramidis and other pipeline candidates, could attract more investors to BBIO, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100